



THERAPEUTICS

Date: September 24, 2026

Merz Pharmaceuticals, LLC

Notice Regarding **INBRIJA® (levodopa inhalation powder)**
National Drug Code Numbers Update and Impact on 340B Virtual Inventory Management

Merz Pharmaceuticals, LLC has asked the Office of Pharmacy Affairs (OPA) to post this notice on the OPA's public website to notify 340B covered entities that the National Drug Code (NDC) number for **INBRIJA® (levodopa inhalation powder)** for **inhalation use** has been transitioned to a new NDC on September 14, 2026, as follows:

These NDC changes will not be accompanied by product packaging changes.

Product Description	Old/Existing NDC	New/Replacement NDC	Effective Date
INBRIJA 42 mg HPI 60 ct	10144-0342-60	00259-6142-60	09/14/2026

The new NDC will not signify any change in product form, strength, or composition. Because each new **INBRIJA® (levodopa inhalation powder)** NDC represents the same product as the corresponding old NDC, **Merz Pharmaceuticals, LLC** will permit eligible 340B covered entities that use a compliant 340B inventory replenishment model to count accumulations of each old NDC toward replenishment of equal quantities for each corresponding new NDC.

The new NDCs are available as of **September 14, 2026**. Merz Pharmaceuticals, LLC will sell its remaining inventory of each old NDC until it is exhausted, at which point Merz Pharmaceuticals, LLC will begin distributing the corresponding new NDC. **Merz Pharmaceuticals, LLC** or your distributor will communicate further information regarding the availability of each new NDC. *Chargebacks and returns will continue to be processed for the old NDCs.*

For any questions regarding this notice contact althea.danzey@merz.com and Therapeutics.Contractops@merz.com.

Thank you for your attention.